Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis

The ibandronate strategy is unlikely to be considered cost effective by decision makers in men or women with characteristics of those in the target population of the RCT, or in older populations with osteoporosis. </AbstractSection> Copyright Adis Data Information BV 2008

MoreLess

Year of publication:	2008
Authors:	Kreck, Simon ; Klaus, Jochen ; Leidl, Reiner ; Tirpitz, Christian ; Konnopka, Alexander ; Matschinger, Herbert ; König, Hans-Helmut
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 26.2008, 4, p. 311-328
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001583